{
    "clinical_study": {
        "@rank": "72396", 
        "brief_summary": {
            "textblock": "To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.\n\n      Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with\n      psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of\n      etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in\n      treating psoriasis in patients without HIV infection by reducing skin involvement and\n      clearing of the condition, but it has not been thoroughly evaluated in HIV-infected\n      patients."
        }, 
        "brief_title": "Treatment of Psoriasis Using Acitretin in HIV-Positive Patients", 
        "condition": [
            "HIV Infections", 
            "Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with\n      psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of\n      etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in\n      treating psoriasis in patients without HIV infection by reducing skin involvement and\n      clearing of the condition, but it has not been thoroughly evaluated in HIV-infected\n      patients.\n\n      Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative\n      assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment\n      continues for a total of 20 weeks. Patients are followed every 2 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Any nondermatologic medication.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Psoriasis involving at least 10 percent of body surface."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002143", 
            "org_study_id": "239A", 
            "secondary_id": "65-93(2)"
        }, 
        "intervention": {
            "intervention_name": "Acitretin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acitretin"
        }, 
        "keyword": [
            "Psoriasis", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Acitretin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10003"
                }, 
                "name": "Beth Israel Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Psoriasis Using Acitretin in HIV-Positive Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002143"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "Beth Israel Med Ctr": "40.714 -74.006"
    }
}